UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPR	OVAL
OMB Number:	3235-0287
Estimated average	burden
hours per response	0.5

longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

(Print or Type Responses)

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Pridgen W		Reporting Person * 2. Issuer Name and Ticker or Trading Symbol Virios Therapeutics, Inc. [VIRI]							5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner									
(Last) (First) (Middle) C/O VIRIOS THERAPEUTICS, INC., 44 MILTON AVENUE				3. Date of Earliest Transaction (Month/Day/Year) 01/28/2021										Officer (give	e title below)	Oth	er (specify bel	ow)
A I DII A D	ETTA C	(Street)	4	4. If Amendment, Date Original Filed(Month/Day/Year)								6. Individual or Joint/Group Filing(Check Applicable Line) _X_Form filed by One Reporting Person _Form filed by More than One Reporting Person						
ALPHAR (City)	ETTA, GA	(State)	(Zip)				Table	e I - No	n-Deriv	vative S	Securitie	s Acqui	red. D	Disposed	of, or Bene	ficially Own	ed	
1.Title of Se (Instr. 3)	ecurity		2. Transaction Date (Month/Day/Year)	2A. Deemed 3. T Execution Date, if Coo		Transaction ode nstr. 8)		4. Securities Acquire (A) or Disposed of (I (Instr. 3, 4 and 5) (A) or		uired of (D)	d 5. Amount of Sec		Securities Beneficially ing Reported		6. Ownership Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)		
C	C41-		01/29/2021					ode		mount	(D)	Price	727.0	202			(Instr. 4)	
Common			01/28/2021 01/29/2021					M P		,500	A	C	7 3,500 3,500				D I	401(k) Account
			Table II -					ir d cquired	n this f isplay: I, Dispo	orm and a cuntile seed of,	re not re rrently v	equired valid O	to re	espond ontrol n	unless the	ion contair form	Sec Sec	1474 (9-02)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security		3A. Deemed	4. Transac Code	4. 5. Number Of		Expiration Date (Month/Day/Year) of U Section (Ins			7. Title of Und Securit	Title and Amount f Underlying ecurities nstr. 3 and 4) 8. Price of Derivative Security (Instr. 5) Bene Own Follo Repo			Owners Form of Derivat Securit Direct or India	ive Ownerships: (Instr. 4) D) ect			
				Code	V	(A)	(D)	Date Exerci	sable	Expir Date	ration	Title		Amount or Number of Shares				
Warrant to Purchase Common Stock	\$ 7.8	01/28/2021(2)		М				12/16	5/2020	01/2	0/2021	Comr Stoo		801	\$ 0	0	D	

Reporting Owners

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Pridgen William C/O VIRIOS THERAPEUTICS, INC. 44 MILTON AVENUE ALPHARETTA, GA 30009	X					

Signatures

/s/ Greg Duncan, Attorney-in-Fact for William Pridgen	02/01/2021

**Signature of Reporting Person	Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The number of shares reported are indirectly held within the Reporting Person's 401(k) account and are invested in the Tuscaloosa Surgical Assoc PC 401k U/A Dtd Jan 1, 2001 of which the Reporting Person is trustee.
- (2) The Reporting Person provided notice of exercise to the Issuer on January 20, 2021 and the Company authorized the issuance of the shares pursuant to such exercise on January 28, 2020.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.